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Available online 20 September 2007Oxidative stress and mitochondrial dysfunction caused by loss of complex I activity are
presumed to be primary events leading to neurodegeneration in Parkinson's disease.
Mitochondrial glutaredoxin (Grx2), a glutathione-dependent thiol disulfide oxidoreductase
helps maintain redox homeostasis in the mitochondria. We therefore, examined the
constitutive expression of Grx2 in brain and its role in MPTP-mediated mitochondrial
dysfunction in the extrapyramidal system. Grx2 is constitutively expressed in both neuron
and glia in mouse and human brain including the neurons in human substantia nigra. Grx2
mRNA and protein were transiently upregulated in midbrain and striatum 1 h but not 4 h
after a single dose of MPTP. Downregulation of Grx2 using antisense oligonucleotides, in
vivo, in mouse brain resulted in partial loss of complex I activity indicating that Grx2 may
help maintain complex I function in the mitochondria. Further, overexpression of Grx2
abolished MPP+-mediated toxicity in vitro in neuroblastoma cells. Our results demonstrate
the probable role of Grx2 in maintenance of the redox milieu in mitochondria and its
potential neuroprotective role in preserving mitochondrial integrity in neurodegenerative
diseases, such as Parkinson's disease.
© 2007 Elsevier B.V. All rights reserved.Keywords:
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Oxidative modification of cellular macromolecules and reduced
levels of antioxidants have been detected in the brains of
Parkinson's disease patients specifically in the substantia nigra
(Jenner, 1998). Further, there is increasing evidence for involve-
ment of mitochondria in neurodegenerative diseases including
Parkinson's disease (PD; Park et al., 2006; Ohta and Ikuroh
Ohsawa, 2006), wherein complex I dysfunction has been identi-
fied in mitochondria from platelet, brain and muscle of Parkin-.
ranath).
enylindole; Grx2, mitoch
er B.V. All rights reservedson's disease patients (Parker et al., 1989; Mizuno et al., 1995).
Selective loss of GSH,which precedes the inhibition ofmitochon-
drial complex I activity, has been reported to occur not only in PD
(Perry et al., 1982) but also in animal models of PD (Sriram et al.,
1997). A major consequence of oxidative stress in brain mito-
chondria following loss of glutathione (GSH) is the formation of
protein–glutathione mixed disulfides leading to modification of
proteins rather than increase in the levels of oxidized glutathione
(GSSG) as seen in liver mitochondria (Ravindranath and Reed,
1990). Thus, maintenance of mitochondrial function duringondrial glutaredoxin 2; MPTP, 1-methyl-4-phenyl-1,2,3,6,tetrahy-
.
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that can reduce protein disulfides to active thiols.
In mammalian cells, thiol homeostasis is maintained
predominantly by thioredoxin and glutaredoxin systems.
Glutaredoxins belong to a family of small proteins havingFig. 1 – Constitutive expression and localization of Grx2 in mous
brain using RT-PCR (A). An amplicon of 549 bp was generated (La
indicates negative control. (B) Total RNA frommouse brain (lanes
and hybridized with sense (lanes1 and 2) and antisense riboprob
ribosomal RNA is indicated. The expression of Grx2 in mouse br
hybridization of coronal sections frommouse brain showing the p
the differential fluorescence in the laminar architecture of the cor
probe do not show any fluorescence (D). Intense fluorescent labe
express Grx2mRNA (E). The inner granular layer (arrow) of the cer
(arrowhead). The reticular neurons of the midbrain expressed Grx
cell layer and the granule cells of dentate gyrus (arrow) in the hi
neurons of CA3 subfield in the hippocampus is shown (arrowhe
The habenular nucleus (arrowhead) and the paraventricular nuc
cells of the corpus callosum (arrowhead) were also intensely fluor
stained (Q). Corresponding control sections hybridizedwith the se
100 μm except in panels C, K, O, P, Q, R (scale bar=50 μm) and Gthiol disulfide oxidoreductase activity and are present both in
the cytosol (Grx1) and mitochondria (Grx2; Gladyshev et al.,
2001). The cytosolic and mitochondrial glutaredoxin share
about 36% sequence identity (Lundberg et al., 2001). Grx2 has a
predicted size of 18 kDa and contains the active site sequencee brain. The complete ORF of Grx2 was amplified frommouse
nes 1 and 2) ‘M’ indicates molecular weight marker and ‘Ne’
1 and 3, 15 μg; and lanes 2 and 4, 30 μg) was electrophoresed
es (lanes 3 and 4) for Grx2. The mobility of the 18S and 28S
ain is seen as a band corresponding to 500 bp. (C) In situ
resence of Grx2mRNA in the neurons of cerebral cortex. Note
tex. Corresponding control section hybridized with the sense
ling of the Purkinje cells in the mouse cerebellum which
ebellumwasmore intensely labeled than themolecular layer
2 mRNA (G). Intense fluorescence was seen in the pyramidal
ppocampus. The presence of Grx2 mRNA in the pyramidal
ad; I). Grx2 expression was seen in the olfactory neurons (K).
leus of the thalamus (arrow) expressed Grx2 mRNA (M). Glial
escent (O). The neurons in the caudate putamen are intensely
nse probe are depicted as (F, H, J, L, N, P, R). Scale bar indicates
(scale bar=25 μm).
10 B R A I N R E S E A R C H 1 1 8 5 ( 2 0 0 7 ) 8 – 1 7“CSYC”, which is different from the conserved “CPYC” motif
present in Grx1. It is present both in the nucleus and mito-
chondria depending on whether transcription starts from the
first or second ATG start codon (Lundberg et al., 2001). Grx2
protects against oxidative stress induced by mitochondrial
damage (Daily et al., 2001a,b) and siRNA-mediated knockdown
of Grx2 sensitizes HeLa cells to cell death induced by
doxorubicin/adriamycin and phenylarsine oxide (Lillig et al.,
2004). Further, the overexpression of Grx2 decreased the
susceptibility to apoptosis (Enoksson et al., 2005). The role of
Grx2 in maintaining the redox milieu of mitochondria during
oxidative stress has been studied in cultured cells. However,
the cell culture models have unavoidable limitations and
animal studies are critical in determining the central role
played by glutaredoxin in the mitochondria.
MPTP mediated mitochondrial dysfunction plays a major
role in the degeneration of substantia nigra pars compacta
neurons in animalmodels (Nicklas et al., 1985). Using theMPTP
mousemodel of PD,wehave shown the role of cytosolicGrx1 in
maintaining complex I activity in the mitochondria. Down-
regulation of cytosolic glutaredoxin using antisense oligonu-
cleotides prevented the recovery of complex I in the striatum
after MPTP treatment, providing support for the critical role of
glutaredoxin in the recovery ofmitochondrial function in brain
(Kenchappa and Ravindranath, 2003). Complex I contains
several cysteine residues in its active site (Dupuis et al.,
1991), and the facile glutathionylation of thiol groups in the
enzyme by reactive oxygen species can potentially result in
inhibition of the enzyme. Our earlier studies show that the
complex I inhibition caused by MPTP can be reversed by
dithiothreitol, further confirming that protein thiol oxidation
is a primary cause for complex I inhibition (Annepu and
Ravindranath, 2000). Therefore, maintenance of protein thiol
homeostasis is critical for preserving the functional activity of
complex I.
Grx2 de-glutathionylates mitochondrial proteins, such as
complex I, which form mixed disulfides during oxidative
conditions in bovine heart mitochondria (Beer et al., 2004).
However, little is known about the interplay between the
mitochondrial and cytosolic glutaredoxin in maintaining the
integrity and functionality of mitochondrial complex I, in vivo.
We therefore studied the constitutive expression and locali-
zation of Grx2 in mouse and human brain and examined its
functional role in MPTP-mediated mitochondrial toxicity in
mice.Fig. 2 –Effect of MPTP on Grx2 mRNA and protein levels. (A) Repr
(Cyt) fractions prepared from whole brain homogenate immunos
tochemical detection of Grx2 is depicted in green, while staining
MitoTracker staining colocalizes with Grx2 indicating the specific
shows a confocal image of a cell with the mitochondria highligh
bar=5 μm). (C) Mice were sacrificed 1 and 4 h after a single dose
control andMPTP-treated animals immunostainedwith antiseru
protein. Densitometric analysis of the immunoblots representing
control (dark grey bar), 1 (grey bar) and 4 h (empty bar) MPTP-tre
indicate values significantly different from corresponding contro
midbrain following 1 h of MPTP treatment. A representative north
MPTP-treated mice (M; n=3 for each time point). Densitometric an
hybridized bands are represented.2. Results
2.1. Amplification of the open reading frame of Grx2 from
mouse brain and its localization
We amplified the complete ORF of Grx2 by RT-PCR using total
RNA frommouse brain (Fig. 1A). The sequencing of the RT-PCR
product revealed complete sequence identity with mouse
Grx2. The sequence had 86% homology to human Grx2.
Northern blot analysis of total RNA from mouse brain cortex
provided further evidence for its constitutive expression in
mouse brain (Fig. 1B). Grx2 was localized in mouse brain using
fluorescent in situ hybridization (FISH). In mouse brain, Grx2
mRNAwas localized in the neurons of cerebral cortex (Fig. 1C),
Purkinje cells of the cerebellum (Fig. 1E) and reticular neurons
of midbrain (Fig. 1G). Intense fluorescence was seen in the
hippocampus, in the pyramidal neurons of CA1, CA2 and CA3
subfields and in the granule cell layer of dentate gyrus (Fig. 1I)
and in the olfactory bulb (Fig. 1K). The habenular and para-
ventricular nucleus of the thalamus (Fig. 1M) and striatum
(Fig. 1Q) showed distinct Grx2 localization. In the corpus
callosum, the glial cells were stained intensely (Fig. 1O). The
respective controls hybridized using sense probe are also
depicted (Figs. 1D, F, H, J, L, N, P, R).
2.2. MPTP exposure upregulates Grx2 in midbrain and
striatum
The constitutive expression of Grx2 protein was detected
by immunoblot in the mitochondria but not in the cytosol
(Fig. 2A). The specificity of the antiserum was also examined
by immunostaining the cells preloaded with MitoTracker
with antibody to Grx2. Grx2 immunostaining colocalized with
that of MitoTracker indicating that Grx2 was present in the
mitochondria (Fig. 2B). As anticipated, no Grx2 was detectable
in the cytosol (Fig. 2A). Male mice were administrated a single
dose of MPTP (30 mg/kg body weight, s.c.) and sacrificed 1
and 4 h later (n=3 animals for each time point). Grx2 protein
increased significantly at 1 h following MPTP but was not
significantly different at 4 h, both in midbrain and striatum
(Fig. 2C). The increase in protein level was due to transcrip-
tional activation of Grx2 since the mRNA levels were also
increased nearly 2-fold in the midbrain after 1 h of MPTP
treatment (Fig. 2D).esentative immunoblot of mitochondrial (Mit) and cytosolic
tained with antiserum to Grx2 is depicted. (B) Immunocy-
with MitoTracker is shown in red in Neuro2A cells.
ity of the antiserum used (scale bar=10 μm). The lower panel
ted using MitoTracker which colocalizes with Grx2 (scale
of MPTP. A representative blot from midbrain and striatum of
m to Grx2 is depicted. Lanes contained 10μg of mitochondrial
the relative intensity of the immunoreactive bands from
ated animals. Values are mean±SD (n=3 animals). Asterisks
l (p<0.05). (D) Expression of Grx2 mRNA was increased in
ern blot of Grx2 and β-actin frommidbrain of vehicle (C) and
alysis of northern blots depicting the relative intensity of the
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Wedownregulated Grx2 in brain by intrathecal administration
of antisense oligonucleotides (Fig. 3A; n=3 animals for each
time point). Downregulation of Grx2, per se, caused a small but
significant loss (14% decrease) in complex I activity in the
midbrain but the complex I loss in striatum was more pro-
nounced (28% loss; Fig. 3B).2.4. Overexpression of Grx2 abolishes MPP+-mediated
toxicity in Neuro2a cells
Neuro2a cells were transfected with pCMV-Grx2 (Figs. 4A
and B) or empty vector (control) and then exposed to MPP+
(1 mM) for 24 h. Apoptotic cell death was assessed using the
terminal deoxynucleotidyl transferase biotin-dUTP nick end
labeling (TUNEL). Cells transfected with empty vector and
Fig. 3 – Effect of downregulation of Grx2 on complex I loss.
(A) Mice were administered antisense oligonucleotides
(100 μg, twice at 12 h interval) to Grx2 through intrathecal
route and sacrificed 12 h after the last injection. Immunoblot
analysis of Grx2 in midbrain and striatum from control
(C) and antisense (AS) oligonucleotide-treated mice reveals
that antisense oligonucleotides to Grx2 downregulate Grx2
expression. (B) Complex I activity inmidbrain and striatumof
animals treated with antisense oligonucleotides
(as described above). The enzyme activity is expressed as
nanomoles of NADH oxidized/min/mg protein. Complex I
activity inmidbrain of control animals was 55.017±4.835 and
antisense oligonucleotide-treated animals was 46.667±
6.506. Complex I activity in striatum of control animals was
64.303±2.837 and the antisense oligonucleotide-treated
animals was 46.667±6.110. Values are mean±SD (n=3)
animals. Asterisks indicate values significantly different
from vehicle-treated control (p<0.05).
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noreactivity (37±5.7% of cells) as compared to cells not
exposed to MPP+ (7.7±2.5%). Grx2 overexpressing cells ex-
posed to MPP+ revealed less TUNEL immunoreactivity (11.7±
3.2%; Figs. 4C and D) indicating the lowered levels of apoptosis
as compared to control cells exposed to MPP+. Grx2 over-
expressing cells (6.8±4.5%) had similar number of apoptotic
nuclei as cells transfected with empty vector.
2.5. Constitutive expression of Grx2 in human brain
Northern blot analysis demonstrated the constitutive expres-
sion of Grx2 in human brain (Fig. 5A). Further, localization of
Grx2 mRNA using FISH demonstrated the expression of Grx2
across human brain regions. High levels of Grx2 mRNA were
seen in cerebral cortex (Fig. 5C), midbrain (Fig. 5G) and
hippocampus (Fig. 5I), while sections hybridized with the
sense probe showed no fluorescence (Figs. 5D, F, H, J). In the
cerebellum, the Purkinje cells and granular cell layer showed
intense fluorescence (Fig. 5E), while the molecular cell layer
showed sparse staining. Intense fluorescence was seen inpyramidal neurons of CA1, CA2 (data not shown) and CA3
regions of the hippocampus. In the midbrain, the reticular
neurons were selectively labeled indicating the predominant
presence of Grx2 mRNA in these cell populations.
Neurons in the substantia nigra from human brain, which
exhibit dopaminergic phenotype, expressed Grx2 (Fisg. 6A
andB)asexaminedby immunohistochemistrywhile the control
sections stained with non-immune serum did not show
significant staining (Figs. 6C and D). In mouse brain substantia
nigra Grx2 expressing cells (Fig. 6E) colocalized with tyrosine
hydroxylase positive (Fig. 6F) dopaminergic neurons as depicted
in the merged figure (Figs. 6G and H).3. Discussion
Mitochondrial glutaredoxin 2 (Grx2) is a glutathione-depen-
dent oxidoreductase with an active site consisting of Cys-Ser-
Tyr-Cys that helps maintain redox homeostasis in the mito-
chondria. The four cysteine residues present in 2 molecules of
Grx2 are coordinated with iron in a non oxidizable [2Fe–2S]2+
cluster to formdimeric holo Grx2, which is inactive (Lillig et al.,
2005). The cluster is preserved in the presence of glutathione,
while oxidants such as glutathione disulfide promote the
degradation of the dimer leading to the formation of the Grx2
monomer, which results in activation of the enzyme. The
iron–sulfur cluster thus serves as a redox sensor and activates
Grx2 during oxidative stress. We examined the presence of
Grx2 in mouse and human brain and studied its potential role
in maintenance of mitochondrial function by downregulating
Grx2 mRNA, in vivo using antisense oligonucleotides.
The mouse and human Grx2 shared only 86% homology
(Supplementary Fig. 1); therefore, we first cloned mouse Grx2
by RT-PCR amplification of mouse brain RNA (Fig. 1A). Our
experiment demonstrated that Grx2 is expressed ubiquitously
in both mouse and human brain and is localized in both
neuronal and glial cell populations. Importantly, Grx2 could be
localized in themelanized neurons of the substantia nigra, the
very cells that degenerate in Parkinson's disease (Figs. 6A, B).
Interestingly while we observed the preferential localization
of Grx1 mRNA in neuronal cell population (Balijepalli et al.,
2000), in the present study we note that Grx2 is distributed
more ubiquitously in the brain in both neuronal and glial cell
populations.
We observed transient upregulation of Grx2 mRNA and
protein 1 h following MPTP administration (Figs. 2C, D). This
could be due to stress response following the initial oxidative
stress caused by MPTP. Grx2 is known to be upregulated in
yeast Saccharomyces cerevisiae following oxidative insult (Grant
et al., 2000). Here we demonstrate for the first time a similar
upregulation in mammalian brain following MPTP exposure.
Promoter analysis of mouse Grx2 reveals the presence of an
AP1 site (1743 bp upstreamof transcription start site) andNFκB
binding sites (1780,1781,667,666 bp upstream of transcription
start site). Presumably, activation of AP1 or NFκB that is shown
to occur following MPTP administration (Kenchappa and
Ravindranath, 2003) could mediate the upregulation of Grx2
seen after MPTP administration.
We downregulated Grx2 in mouse brain using antisense
oligonucleotides to examine the role of Grx2 in maintenance
Fig. 4 – Overexpression of Grx2 abolishes MPP+-mediated toxicity in Neuro2a cells. (A) Immunostaining for Grx2 in N2A cells
transfected with empty vector (pCMV-MCS; Control) or with pCMV-MCS containing the complete ORF of Grx2 (Grx2) is shown
along with respective DAPI images (scale bar=100 μM). (B) Representative immunoblot stained with Grx2 antiserum of control
and Grx2 overexpressing cells. (C) Cells were exposed to MPP+ (1 mM) for 24 h and the percentage of TUNEL-positive cells vs.
DAPI-stained nuclei were counted from 3 independent experiments. Asterisk indicates values significantly different from
controls (p<0.001). Images of TUNEL positive cells along with corresponding DAPI images are depicted (scale bar=200 μM).
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reduction in complex I activity in both striatum and midbrain
(Fig. 3B). This may be expected since oxidation of critical
subunits in complex I (75 and 52 kDa) through thiol modifi-
cation is known to result in the loss of complex I activity and
Grx2 helps restore complex I activity in vitro in isolated
mitochondria (Taylor et al., 2003). It may be noted that
although Grx2 knockdown was substantial, the loss in
complex I activity was only 14%. This may be due to the fact
that both Grx1 and Grx2 contribute to the maintenance of
complex I activity. We have earlier shown that knockdown of
Grx1 also results in complex I loss (Kenchappa and Ravin-
dranath, 2003) and it is presumable that when Grx2 is
downregulated compensatory mechanisms involving Grx1,
thioredoxins (Trx1 and Trx2) and peroxiredoxins may poten-
tially contribute to the restoration of complex I activity.
Overexpression of Grx2 in Neuro2a cells completely ame-
liorated the apoptotic cell death mediated by MPP+ (Fig. 4),indicating the potential neuroprotective effects of Grx2. Thus,
Grx2 is important for the maintenance of complex I activity, in
vivo in brain and therefore may play an important role in
ensuring mitochondrial integrity in vulnerable neurons, such
as dopaminergic neurons of the substantia nigra pars
compacta that degenerate in PD. Single nucleotide poly-
morphisms that alter the functional activity of Grx2 may
render individuals vulnerable to complex I dysfunction such
as those seen in PD.4. Experimental procedure
4.1. Materials
cDNA to humanmitochondrial glutaredoxin (Grx2) was kindly
provided by Dr. Vadim N. Gladyshev, University of Nebraska,
Lincoln (Gladyshev et al., 2001). DIG-RNA labeling and
Fig. 5 – Constitutive expression and localization of Grx2 in
human brain. (A) Northern blot analysis showing the
constitutive expression of Grx2 mRNA in human brain. Total
RNA from human brain cortex (lanes1, 2; 15 μg) was
electrophoresed and hybridized with sense (lane1) and
antisense riboprobes (lane 2) prepared using cDNA to human
Grx2. The mobility of the 18S and 28S ribosomal RNA are
indicated. The expression of Grx2 in human brain was seen
as band of 500 bp. (B) Localization of Grx2 mRNA in human
brain using fluorescent in situ hybridization. The presence of
Grx2 mRNA was seen in the neurons of cerebral cortex (C).
Intense fluorescence was seen in Purkinje and granule cells
(arrow) of cerebellum. Sparse staining was observed in the
molecular layer (arrowhead; E). The reticular neurons in the
midbrain expressed Grx2 mRNA (G). Intense fluorescence
was seen in the pyramidal cell layer of CA3 region of the
hippocampus (I). Corresponding controls hybridizedwith the
sense probe are depicted in panels D, F, H, J. Scale bar
indicates 50μmexcept in panels F (scale bar=100μm) and G,
D (scale bar=25 μm).
14 B R A I N R E S E A R C H 1 1 8 5 ( 2 0 0 7 ) 8 – 1 7detection kit, antidigoxigenin Fab fragments linked to perox-
idase and alkaline phosphatase were purchased from Roche
Biochemicals (Indianapolis, IN, USA). The tyramide signal
amplification kit was obtained from New England Nuclear
(Boston, MA, USA) and Vectastain-ABC Elite kit was purchased
from Vector labs (Burlingame, CA, USA). All other chemicals
and reagents were of analytical grade and were obtained from
Sigma Chemical Company (St. Louis, MO, USA) or Qualigens
(India).
4.2. Animals
All animal experiments were carried out as per the National
Institute of Health guidelines for the use and care of animals.
All efforts were made to minimize animal suffering, to reduce
the number of animals used and to utilize alternatives to invivo techniques if available. Male C57BL6J mice (2 to 3 months,
25–30 g) were obtained from the Central Animal Research
Facility of National Brain Research Centre (NBRC). Animals
had access to pelleted diet and water ad libitum.
4.3. Human brain samples
Brain tissue from male traffic accident victims were obtained
from the Human Brain Tissue Repository of the National
Institute of Mental Health and Neurosciences, Bangalore,
India, in compliance with the ethical guidelines of the
Government of India. After autopsy, brains were washed in
ice-cold saline and dissected into different regions based on
standard anatomical markings including cortex, hippocam-
pus, midbrain and cerebellum. All regions were fixed in
buffered paraformaldehyde (4%, w/v) for in situ hybridization
studies. For northern blot analysis, brain samples were flash
frozen in liquid nitrogen and stored at −70 °C. The age and
gender of the subjects were: 32 year old male (postmortem
delay 4 h) and 65 year old male (postmortem delay 6 h).
Animals were administered a single dose of MPTP (30 mg/kg
body wt in normal saline, s.c.). Control animals received vehicle
alone. Animals were sacrificed at various times after MPTP
administration. The mice were anesthetized with ether
and perfused transcardially with ice-cold normal saline before
decapitation. Striatum was dissected out as described by
Glowniskyand Iversen (1966). Bregmacoordinatesandanatomic
boundaries were established for dissection of ventral midbrain
based on the mouse brain atlas (Paxinos and Franklin, 2001).
Briefly, the skull plates were peeled away to visually locate the
bregma. Thebrainwas removed fromtheskull andplaceddorsal
sideup.Usingascalpel blade, a coronal cutwasmadeadjacent to
the inferior colliculi approximately at bregma −6.36 mm. A
second cut was made approximately at bregma −2.54 mm. The
slice was placed rostral side up and the ventral midbrain was
dissected out ensuring that there was no contamination of the
hippocampus, cortex or cerebellum. The dissected brain regions
were immediately frozen in liquid nitrogen.
4.4. Amplification of Grx2 by RT-PCR using mouse brain
RNA
Total RNA was isolated from mouse brain using TRI reagent
(Chomczynski, 1993). One-step RT-PCRwas performed accord-
ing to the manufacturer's protocol (Qiagen, GmbH, Germany)
using the following forward and reverse primers; 5′ to 3′-
AGCTGCCGGGGACCTTTG (representing bases from 16 to 33)
and 3′ to 5′-GTCAAAGGTACGACTGCACTA (representing bases
from 484 to 504). The primers were designed to amplify the
coding sequence starting from the mitochondrial transloca-
tion signal of exon 1. The expected size of the PCR product is
549 bp. Negative control was devoid of template DNA. The PCR
products were analyzed by agarose gel electrophoresis and
cloned into pCR 2.1 vector (Invitrogen). Identity of the product
was confirmed by sequencing. The Grx2 gene was further
subcloned into pBluescript and sequence verified. The cDNA
of human Grx2 present in pET vector was subcloned into
pBluescript vector and verified by sequencing. These clones
were used to synthesize sense and antisense riboprobes for
northern blot analysis and in situ hybridization.
Fig. 6 – Localization of Grx2 in human and mouse brain substantia nigra by immunohistochemistry. Grx2 is expressed in
substantia nigra (arrow; A) of human brain as seen by immunohistochemistry using antiserum to Grx2. A highermagnification
of panel A shows prominent immunostaining in nigral neurons (B). The respective control section treated with non-immune
serum (C) and itsmagnified image (D) are depicted. Arrow indicates themelanin laden dopaminergic pars compacta population
of cells (C). Scale bar=100 μm (A, C) and scale bar=25 μm (B, D). Immunostaining of mouse brain substantia nigra with antisera
to tyrosine hydroxylase (F) and Grx2 (E) is depicted. The merged image indicates the colocalization of Grx2 and tyrosine
hydroxylase in substantia nigra (G and H). Scale bar=100 μm (E–G) and scale bar=5 μm (H).
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Brain regions were homogenized in 0.25 M sucrose and
centrifuged at 1000×g for 10 min to obtain the nuclear pellet
and post-nuclear supernatant which was again centrifuged at
17,000×g for 30 min to obtain mitochondrial pellet. The
mitochondrial pellet was suspended in 0.25 M sucrose and
freeze–thawed for the assay of complex I and immunoblot
analyses. Cytosol was prepared by ultracentrifugation of thehomogenate at 65,000 rpm for 1 h. Protein concentration was
estimated by a dye binding method (Bradford, 1976).
4.6. Northern blot analysis and fluorescent in situ
hybridization
Constitutive expression and localization of Grx2 was exam-
ined by northern blot analysis (Kevil et al., 1997) and fluores-
cent in situ hybridization (Balijepalli et al., 2000), respectively,
16 B R A I N R E S E A R C H 1 1 8 5 ( 2 0 0 7 ) 8 – 1 7using digoxigenin labeled sense and antisense riboprobes
prepared using the cDNA to mouse and human brain Grx2.
4.7. Preparation of antiserum to Grx2
Antiserum to Grx2 was raised in New Zealand white rabbits
(Kamataki et al., 1976). The 14 amino acid peptide (CNYKV-
VELBLLEYG) was conjugated with bovine serum albumin at
the N-terminal and used as antigen. This peptide sequence
shared 93% homology with human Grx2 (NYKVVELDLLEYG)
and 79% homology with mouse Grx2 (NYKAVELDMLEYG). The
antiserum was used for immunoblotting and immunohisto-
chemistry of Grx2 of both mouse and human origin.
4.8. Immunoblot analysis
Immunoblot analysis was performed using mitochondria from
midbrainof vehicleandMPTP-treatedmice. Proteinswere trans-
ferred to nitrocellulose membranes (Towbin et al., 1979), incu-
bated with antibody to Grx2 followed by incubation with anti-
rabbit IgG labeled with alkaline phosphatase. Immunostained
bandsweredetectedusingnitroblue tetrazoliumand5-bromo4-
chloro 3-indolyl phosphate as chromogens or using chemilumi-
nescence kit (ECL, Amersham Pharmacia Biotech, France).
4.9. Immunohistochemistry
Humanbrain obtained at autopsywas fixed in 4% (w/v) buffered
paraformaldehyde, processed for paraffin embedding and serial
sections (8–10 μm thick) were cut. Sections were dewaxed,
hydrated in graded alcohol and PBS (10 mM, pH 7.4, PBS). The
sections were blocked with normal goat serum for 30 min at
room temperature and incubated with antiserum to Grx2
(diluted to 1:1000 in PBS) at 37 °C for 2 h. After washing, they
were incubated in biotinylated anti-rabbit IgG solution (1:500
dilution) for 1 h at room temperature. After further washing,
they were incubated with VECTASTAIN Elite ABC reagent for
30 min at room temperature. The sections were then washed
briefly in PBS followed by water. The color was developed using
diaminobenzidine and mounted using Permont (Chinta et al.,
2002). The sameprocedurewas followed for thenegative control
except for the primary antibody was substituted for normal
rabbit IgG. In a separate set of experiments, immunostaining
was visualized using FITC labeled secondary antibody and the
sections were counterstained with DAPI.
Neuro 2a cells were seeded in a chamber slide to 50% con-
fluency 24 h before fixation. Mitochondria were stained with
MitoTracker Deep Red 633 (Molecular Probes) at 37 °C prior to
fixation with 4% paraformaldehyde at room temperature for
30min. For immunostainingwithGrx2, cellswerewashedwith
PBS and permeabilized with digitonin (0.01%; w/v) followed
by overnight incubation with antisera to Grx2 at 4 °C. After
washing with PBS, cells were incubated with secondary anti-
body (FITC tagged) for 1 h at roomtemperature. Finally the cells
were mounted in mounting medium containing DAPI. Images
were taken using confocal microscope.
4.10. Overexpression of Grx2 and MPP+ toxicity
Neuro2a cells were plated in chamber slide at a cell density of
2×104 cells per well 24 h prior to transfection with pCMV-MCS(empty vector as control) and pCMV-Grx2 containing the
complete coding sequence of mouse Grx2. After 24 h of
transfection, cells were exposed toMPP+ (1mM) or vehicle for a
further period of 24 h following which they were fixed with 4%
paraformaldehyde (w/v). The cells were then permeabilized
with 0.02% (v/v) Triton-X 100 and the TUNEL reaction was
carried out using “In situ cell death detection kit, fluorescein”
(Roche Indianapolis, IN) according to manufacturer's instruc-
tion. The cells were then washed with PBS (1X) and DNA
fragmentation was detected by labeling with fluorescein
labeled dUTP using terminal deoxynucleotidyl transferase
and examined using a fluorescence microscope at excitation
wavelength of 488 nm. The total cell nuclei were counted by
counterstaining with 4′, 6′-diamidino-2-phenylindole (DAPI)
at excitation wavelength, 350 nm.
4.11. Assay of NADH:ubiquinone oxidoreductase
(Complex I)
Complex I was assayed in mitochondria as rotenone-sensitive
NADH-ubiquinone oxidoreductase (Kenchappa and Ravin-
dranath, 2003). The assay was performed in 35 mM potas-
sium phosphate buffer, pH 7.4, containing sodium cyanide
(2.65 mM), magnesium chloride (5 mM), EDTA (1 mM), bovine
serum albumin (1 mg/ml) and antimycin (2 μg/ml). Brain
mitochondria (70–80 μg) and ubiquinone 1 (0.05 mM) were
added to the assay buffer to a final volume of 0.48 ml. After
preincubation of the reaction mixture at room temperature
for 2 min, the reaction was initiated by addition 0.02 ml of
5 mM NADH solution. Test and blank reactions were run
separately using a single beam spectrophotometer. The rate
of decrease of absorbance at 340 nm (0.04–0.09/min) was
monitored over 3 min. The assay was also performed in the
presence of rotenone to determine the rotenone-sensitive
enzyme activity that was 80% of the total activity. The en-
zyme activity is expressed as nanomoles of NADH oxidized
per min per mg of protein.
4.12. Downregulation of Grx2 expression in mouse brain
using antisense oligonucleotides
Antisense phosphorothionate end-capped oligonucleotides
(19 mer) originating from the start codon of Grx2 cDNA
(antisense: ATGTCCTGGCGCCGCGCGG) were injected intra-
thecally into mice at 100 μg/dose, twice at 12 h intervals.
The downregulation of Grx2 was examined by immunoblot
analysis 12 h after the last injection of oligonucleotides.
The striatum and midbrain of the animals were dissect-
ed out and complex I activity was assayed as described
earlier.
Statistical analysis was performed using Student's t test or
ANOVA followed by Student–Newman–Keuls or Dunnett's test
as appropriate.Acknowledgments
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